What is the bone mineral density (BMD) image age?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Bone mineral density (BMD) images should be repeated every 1-2 years for patients on osteoporosis treatment to monitor therapy effectiveness, and every 2-3 years for those being screened or at risk but not on treatment, as recommended by the most recent guidelines 1.

Key Considerations

The timing of BMD image repetition depends on individual risk factors, including:

  • Age: women 65 years and older, and men 70 years and older, should be screened for osteoporosis 1
  • Gender: women are at higher risk of osteoporosis than men 1
  • Previous fractures: individuals with a history of fractures should be screened for osteoporosis 1
  • Medication use: especially corticosteroids, which can increase the risk of osteoporosis 1
  • Rate of bone loss: individuals with rapidly declining BMD should be monitored more frequently 1

Risk Factors

Certain medical conditions and medications can increase the risk of osteoporosis, including:

  • Chronic renal failure
  • Rheumatoid arthritis and other inflammatory arthritides
  • Eating disorders
  • Organ transplantation
  • Prolonged immobilization
  • Conditions associated with secondary osteoporosis
  • Glucocorticoid therapy for >3 months
  • Hypogonadal men >18 years of age
  • Medications known to adversely affect BMD, such as anticonvulsant drugs and androgen deprivation therapy 1

Monitoring Intervals

The monitoring interval for BMD images should be individualized based on the patient's clinical circumstances, with more frequent imaging recommended for patients with significant risk factors or rapidly declining BMD 1.

  • For patients on osteoporosis treatment, monitoring every 1-2 years is recommended 1
  • For patients being screened or at risk but not on treatment, monitoring every 2-3 years is recommended 1
  • For stable patients with normal BMD or mild osteopenia, testing can be extended to 5-10 years 1

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

BMD Image Age

  • The age at which bone mineral density (BMD) images are typically taken is not explicitly stated in the provided studies.
  • However, the studies suggest that BMD measurements are usually taken in individuals who are at risk of osteoporosis, such as postmenopausal women and older adults 2, 3.
  • The World Health Organization (WHO) criteria define osteoporosis as low bone mineral density, with a T-score ≤ -2.5 found in the spine, the neck of the femur, or during a full hip examination, which can be applied to individuals of any age 4.
  • One study found that female gender, aging, and increased serum calcium level were significantly related to decreasing femoral BMD, suggesting that BMD measurements may be more relevant for older adults and women 5.
  • Another study recommended that all women 65 and older should be screened for osteoporosis, and that younger postmenopausal women with elevated risk should also be considered for screening 2.

Risk Factors for Low BMD

  • Several studies identified risk factors for low BMD, including:
    • Age 3, 5
    • Female gender 5
    • Low body mass index (BMI) 5
    • Elevated serum calcium level 5
    • Vitamin D deficiency 4
    • Smoking 4
    • Alcohol consumption 4
    • Low calcium intake 4
    • Sedentary lifestyle 4
  • These risk factors can be used to identify individuals who may be at risk of osteoporosis and who may benefit from BMD measurements 3, 4, 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Osteoporosis: screening, prevention, and management.

The Medical clinics of North America, 2015

Research

Osteoporosis - risk factors, pharmaceutical and non-pharmaceutical treatment.

European review for medical and pharmacological sciences, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.